ISIN:DE0005313704
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
Carl Zeiss Meditec generated revenue of €475.0m in the first quarter of fiscal year 2023/24 (prior year: €470.3m), corresponding to a growth of +1.0% (adjusted for currency effects: +3.3%).
- Carl Zeiss Meditec generated revenue of €475.0m in the first quarter of fiscal year 2023/24 (prior year: €470.3m), corresponding to a growth of +1.0% (adjusted for currency effects: +3.3%).
- Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG commented on the Q1 results: “We have made a solid start to the new fiscal year.
- The strategic business unit Microsurgery achieved revenue growth of +10.6% (adjusted for currency effects: +13.7%) to €123.9m (prior year: €112.0m).
- The APAC [2] region recorded a slight decline in revenue of -0.9% (adjusted for currency effects: +0.4%), to €206.4m (prior fiscal year: €208.2m).
EQS-News: U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS
The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.
- The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.
- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
- With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
- For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .
EQS-News: VISUMAX 800 mit SMILE pro Software von ZEISS erhält FDA-Zulassung in den USA
U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS
DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe.
- DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
- The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.
- With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
- For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .
U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS
DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe.
- DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
- The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.
- With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
- For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .
EQS-News: Carl Zeiss Meditec steigert Umsatz im Geschäftsjahr 2022/23 um rund 10 Prozent
EQS-News: Carl Zeiss Meditec increased revenue in fiscal year 2022/23 by around 10 percent
Carl Zeiss Meditec generated revenue of €2,089m in fiscal year 2022/23 (prior year: €1,903m), corresponding to growth of +9.8% (adjusted for currency effects: +10.1%).
- Carl Zeiss Meditec generated revenue of €2,089m in fiscal year 2022/23 (prior year: €1,903m), corresponding to growth of +9.8% (adjusted for currency effects: +10.1%).
- Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG: “We were able to further expand our market shares in both strategic business units despite an increasingly weakening economy.
- Revenue in the strategic business unit (SBU) Ophthalmology increased by +7.3% in fiscal year 2022/23 (adjusted for currency effects: +7.6%), to €1,576m (prior year: €1,469m).
- Good progress in equipment deliveries during the course of the fiscal year was a major contributor to revenue growth.
EQS-News: Carl Zeiss Meditec AG kündigt Vereinbarung zur Übernahme von Dutch Ophthalmic Research Center (D.O.R.C.) an
EQS-News: Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)
Carl Zeiss Meditec AG announced today that it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Center (International) B.V.
- Carl Zeiss Meditec AG announced today that it has entered into an agreement to acquire 100% of the shares in Dutch Ophthalmic Research Center (International) B.V.
- Their innovative portfolio of devices, disposables and liquids for ophthalmic surgeries are a strong complement to the ZEISS Medical Technology portfolio.
- “With the acquisition of Dutch Ophthalmic Research Center, we’ll bring together two highly innovative ophthalmic powerhouses to accelerate ZEISS’s position in the vitreo-retinal surgery segment and extend our leadership in the ophthalmic medical devices market,” says Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG.
- celebrates 40 years of innovation in ophthalmic surgery, we could not be more excited to join a market leader and visionary like ZEISS Medical Technology,” says Pierre Billardon, CEO of Dutch Ophthalmic Research Center, International.